Clarithromycin resistance and female gender affect Helicobacter pylori eradication failure in chronic gastritis
0
조회
0
다운로드
6
인용
0
참고문헌
키워드
초록
Background/Aims: The eradication rate of the first-line triple therapy (a proton pump inhibitor, clarithromycin, and amoxicillin) for Helicobacter pylori infection has gradually decreased in Korea. We evaluated whether clinical parameters, clarithromycin resistance, and CYP2C19 genotype can affect the eradication failure. Methods: A total of 203 patients with H. pylori-positive chronic gastritis were consecutively enrolled. They received clarithromycin-based triple therapy for 7 days. A clarithromycin resistance test was performed by detection of A2142G and A2143G point mutations in H. pylori 23S rRNA. The CYP2C19 genotype was examined for polymorphism G681A of exon 5 and G636A of exon 4 by polymerase chain reaction with restriction fragment length polymorphism. Eradication was assessed by a 13C-urea breath test 4 weeks after treatment. Results: Of 203 patients, 190 completed the study. The eradication rate was 64.0% according to intention-to-treat analysis and 68.4% by per-protocol analysis. CYP2C19 genotypes were identified as follows: 75 poor metabolizers, 75 intermediate metabolizers, and 40 rapid metabolizers. Nonetheless, this polymorphism was not significantly associated with eradication failure (p = 0.682). Clarithromycin resistance was detected in 33/190 patients (17.4%), and their eradication rate was zero. Clarithromycin resistance (odds ratio [OR], 19.13; 95% confidence interval [CI], 9.35 to 35.09) and female gender (OR, 1.73; 95% CI, 1.15 to 4.25) were significantly associated with eradication failure. The other clinical parameters such as age, cigarette smoking, alcohol intake, the body mass index, hypertension, and diabetes were not significantly associated with eradication. Conclusions: Clarithromycin resistance and female gender are factors affecting H. pylori eradication failure in patients with chronic gastritis.
Abstract
Background/Aims: The eradication rate of the first-line triple therapy (a proton pump inhibitor, clarithromycin, and amoxicillin) for Helicobacter pylori infection has gradually decreased in Korea. We evaluated whether clinical parameters, clarithromycin resistance, and CYP2C19 genotype can affect the eradication failure. Methods: A total of 203 patients with H. pylori-positive chronic gastritis were consecutively enrolled. They received clarithromycin-based triple therapy for 7 days. A clarithromycin resistance test was performed by detection of A2142G and A2143G point mutations in H. pylori 23S rRNA. The CYP2C19 genotype was examined for polymorphism G681A of exon 5 and G636A of exon 4 by polymerase chain reaction with restriction fragment length polymorphism. Eradication was assessed by a 13C-urea breath test 4 weeks after treatment. Results: Of 203 patients, 190 completed the study. The eradication rate was 64.0% according to intention-to-treat analysis and 68.4% by per-protocol analysis. CYP2C19 genotypes were identified as follows: 75 poor metabolizers, 75 intermediate metabolizers, and 40 rapid metabolizers. Nonetheless, this polymorphism was not significantly associated with eradication failure (p = 0.682). Clarithromycin resistance was detected in 33/190 patients (17.4%), and their eradication rate was zero. Clarithromycin resistance (odds ratio [OR], 19.13; 95% confidence interval [CI], 9.35 to 35.09) and female gender (OR, 1.73; 95% CI, 1.15 to 4.25) were significantly associated with eradication failure. The other clinical parameters such as age, cigarette smoking, alcohol intake, the body mass index, hypertension, and diabetes were not significantly associated with eradication. Conclusions: Clarithromycin resistance and female gender are factors affecting H. pylori eradication failure in patients with chronic gastritis.
참고문헌 (39)
- Lim SH, "Prevalence and risk factors of Helicobacter pylori infection in Korea : nationwide multicenter study over 13 years", BMC Gastroenterol, 13, pp.104~ (2013)
- Franchini M, "Effect of Helicobacter pylori eradication on platelet count in idiopathic thrombocytopenic purpura : a systematic review and meta-analysis", J Antimicrob Chemother, 60, pp.237~246 (2007)
- McColl KE, "Clinical practice. Helicobacter pylori infection", N Engl J Med, 362, pp.1597~1604 (2010)
- 조동근, "Helicobacter pylori 제균율 변화와일차 제균에 영향을 미치는 임상 인자", 대한소화기학회지, 55(6), pp.368~375 (2010), 대한소화기학회
- Malfertheiner P, "Peptic ulcer disease", Lancet, 374, pp.1449~1461 (2009)
- Sugimoto M, "Efficacy of tailored Helicobacter pylori eradication treatment based on clarithromycin susceptibility and maintenance of acid secretion", Helicobacter, 19, pp.312~318 (2014)
- 김성은, "Trends in Helicobacter pylori eradication rates by first-line triple therapy and related factors in eradication therapy", The Korean Journal of Internal Medicine, 30(6), pp.801~807 (2015), 대한내과학회[DOI]
- Hwang TJ, "Change in antibiotic resistance of Helicobacter pylori strains and the effect of A2143G point mutation of 23S rRNA on the eradication of H. pylori in a single center of Korea", J Clin Gastroenterol, 44, pp.536~543 (2010)
- Mitchell H, "Epidemiology, clinical impacts and current clinical management of Helicobacter pylori infection", Med J Aust, 204, pp.376~380 (2016)
- Megraud F, "Helicobacter pylori and antibiotic resistance", Gut, 56, pp.1502~ (2007)
- Lee JW, "Prevalence of primary and secondary antimicrobial resistance of Helicobacter pylori in Korea from 2003 through 2012", Helicobacter, 18, pp.206~214 (2013)
- Dickson EJ, "Genetics of response to proton pump inhibitor therapy : clinical implications", Am J Pharmacogenomics, 3, pp.303~315 (2003)
- Suzuki T, "Smoking increases the treatment failure for Helicobacter pylori eradication", Am J Med, 119, pp.217~224 (2006)
- Lee JY, "Factors affecting first-line triple therapy of Helicobacter pylori including CYP2C19genotype and antibiotic resistance", Dig Dis Sci, 59, pp.1235~1243 (2014)
- Malfertheiner P, "Management of Helicobacter pylori infection-the Maastricht V", Florence Consensus Report, 2017, pp.66, 6~30
- Occhialini A, "Macrolide resistance in Helicobacter pylori : rapid detection of point mutations and assays of macrolide binding to ribosomes", Antimicrob Agents Chemother, 41, pp.2724~2728 (1997)
- Andersson T, "Polymorphic hydroxylation of S-mephenytoin and omeprazole metabolism in Caucasian and Chinese subjects", Pharmacogenetics, 2, pp.25~31 (1992)
- Yoon JH, "Trends in the eradication rates of Helicobacter pylori infection for eleven years", World J Gastroenterol, 18, pp.6628~6634 (2012)
- Park CS, "Pretreatment antimicrobial susceptibility-guided vs. clarithromycin-based triple therapy for Helicobacter pylori eradication in a region with high rates of multiple drug resistance.", Am J Gastroenterol, 109, pp.1595~1602 (2014)
- Zheng Q, "Comparison of the efficacy of triple versus quadruple therapy on the eradication of Helicobacter pylori and antibiotic resistance", J Dig Dis, 11, pp.313~318 (2010)
- De Francesco V, "Prevalence of primary clarithromycin resistance in Helicobacter pylori strains over a 15 year period in Italy", J Antimicrob Chemother, 59, pp.783~785 (2007)
- Francavilla R, "Clarithromycin-resistant genotypes and eradication of Helicobacter pylori", J Pediatr, 157, pp.228~232 (2010)
- Padol S, "The effect of CYP2C19 polymorphisms on H. pylori eradication rate in dual and triple first-line PPI therapies: a meta-analysis", Am J Gastroenterol, 101, pp.1467~1475 (2006)
- Tang HL, "Effects of CYP2C19loss-of-function variants on the eradication of H. pylori infection in patients treated with proton pump inhibitor-based triple therapy regimens: a meta-analysis of randomized clinical trials", PLoS One, 8, pp.e62162~ (2013)
- McNicholl AG, "Meta-analysis: esomeprazole or rabeprazole vs. first-generation pump inhibitors in the treatment of Helicobacter pylori infection", Aliment Pharmacol Ther, 36, pp.414~425 (2012)
- Kang JM, "Effect of the CYP2C19polymorphism on the eradication rate of Helicobacter pylori infection by 7-day triple therapy with regular proton pump inhibitor dosage", J Gastroenterol Hepatol, 23(8 Pt 1), pp.1287~1291 (2008)
- Pratha VS, "Inhibition of pentagastrin-stimulated gastric acid secretion by pantoprazole and omeprazole in healthy adults", Dig Dis Sci, 51, pp.123~131 (2006)
- Cai W, "Variables influencing outcome of Helicobacter pylori eradication therapy in South China", Helicobacter, 14, pp.91~96 (2009)
- Osato MS, "Pattern of primary resistance of Helicobacter pylori to metronidazole or clarithromycin in the United States", Arch Intern Med, 161, pp.1217~1220 (2001)
- Moayyedi P, "Patient factors that predict failure of omeprazole, clarithromycin, and tinidazole to eradicate Helicobacter pylori", J Gastroenterol, 32, pp.24~27 (1997)
- 김태윤, "제주 지역에서 23S rRNA 점 돌연변이와 관련된 Clarithromycin 내성 Helicobacter pylori", 대한소화기학회지, 61(5), pp.252~258 (2013), 대한소화기학회
- Treiber G, "Age-dependent eradication of Helicobacter pylori with dual therapy", Aliment Pharmacol Ther, 11, pp.711~718 (1997)
- Sjostedt S, "Prolonged and profound acid inhibition is crucial in Helicobacter pylori treatment with a proton pump inhibitor combined with amoxicillin", Scand J Gastroenterol, 33, pp.39~43 (1998)
- Murray LJ, "Inverse relationship between alcohol consumption and active Helicobacter pylori infection : the Bristol Helicobacter project", Am J Gastroenterol, 97, pp.2750~2755 (2002)
- Namiot Z, "The effect of cigarette smoking and alcohol consumption on efficacy of Helicobacter pylori eradication", Pol Arch Med Wewn, 104, pp.569~574 (2000)
- Baena JM, "Relation between alcohol consumption and the success of Helicobacter pylori eradication therapy using omeprazole, clarithromycin and amoxicillin for 1 week", Eur J Gastroenterol Hepatol, 14, pp.291~296 (2002)
- Aydemir S, "Helicobacter pylori infection in hemodialysis patients : susceptibility to amoxicillin and clarithromycin", World J Gastroenterol, 11, pp.842~845 (2005)
- Jung SW, "Efficacy of Helicobacter pylori eradication therapy in chronic liver disease", Dig Liver Dis, 41, pp.134~140 (2009)
- Kim N, "Institutional difference of antibiotic resistance of Helicobacter pylori strains in Korea", J Clin Gastroenterol, 40, pp.683~687 (2006)